Nasdaq:RNA
Avidity Biosciences, Inc.
A clinical-stage biopharmaceutical firm developing novel therapies for oncology and rare diseases with a focus on strategic partnerships.
Key Metrics
Investment Thesis
Bull Case
Investors may consider RNA due to its strategic partnerships that provide milestone payments, reducing immediate revenue pressure, and a promising pipeline of potential blockbuster drugs in oncology. The company's strong cash balance allows it to fund operations while advancing clinical trials without immediate need for external financing. Successful trial results could unlock significant value and lead to lucrative licensing deals.
Bear Case
The stock faces significant headwinds given the widening net loss trend from -$174M in 2022 to -$684.6M in 2025, raising concerns about financial sustainability. High operational expenses relative to low revenue of $18.8M suggest a precarious balance sheet dependent on future external funding or successful exits. The risk of clinical trial failure remains high for early-stage biotech firms with limited current earnings power.
About Avidity Biosciences, Inc.
Avidity Biosciences (RNA) is a clinical-stage biopharmaceutical company focused on developing novel therapeutic candidates for oncology and rare diseases. The company primarily serves the global healthcare market through its proprietary asset portfolio, aiming to bring innovative treatments to patients with unmet medical needs. Revenue generation currently stems from strategic partnerships and milestone payments related to its drug development programs.
Analysis
Management Discussion
The company reported a net loss of $684.6M in 2025, reflecting substantial investments in research and development totaling $559.2M and general administrative costs of $205.5M. Despite maintaining a healthy cash position with $385.3M in cash and equivalents, the operating cash flow turned negative at -$650.4M, indicating heavy capital deployment for growth initiatives.
Industry Overview
The biopharmaceutical industry is characterized by long development cycles, high R&D costs, and reliance on regulatory approvals from bodies like the FDA. Companies in this sector often operate at a loss during the development phase, funding progress through equity financing or strategic partnerships before achieving commercialization. Success depends heavily on innovative science, clinical trial outcomes, and the ability to navigate complex reimbursement landscapes.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $9.2M | $9.6M | $10.9M | $18.8M |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $9.2M | $9.6M | $10.9M | $18.8M |
| Operating Expenses | $188.1M | $245.2M | $389.8M | $764.7M |
| Operating Income | $-178.9M | $-235.6M | $-378.9M | $-745.9M |
| R&D | $150.4M | $191.0M | $303.6M | $559.2M |
| G&A | $37.7M | $54.2M | $86.2M | $205.5M |
| Stock-Based Comp | $27.1M | $38.2M | $51.4M | $97.8M |
| Depreciation | $1.4M | $2.1M | $2.8M | $4.2M |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 | $61.3M |
| Interest Expense | $0 | — | — | — |
| Pre-Tax Income | $-178.9M | $-235.6M | $-378.9M | $-684.6M |
| Income Tax | $0 | $0 | $0 | $0 |
| Continuing Ops | $-178.9M | $-235.6M | $-378.9M | $-684.6M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-174.0M | $-212.2M | $-322.3M | $-684.6M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-174.0M | $-212.2M | $-322.3M | $-684.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $622.9M | $611.3M | $1.54B | $1.80B |
| Cash & Equivalents | $340.4M | $185.1M | $219.9M | $382.5M |
| Accounts Receivable | — | $1.1M | $0 | — |
| Prepaid Expenses | $12.2M | $16.0M | $40.8M | $101.6M |
| Other Current Assets | $270.3M | $409.2M | $1.28B | $1.31B |
| Long-Term Assets | $15.9M | $17.2M | $21.6M | $159.6M |
| PP&E (Net) | $6.3M | $8.4M | $12.7M | $23.3M |
| Operating Leases | $8.8M | $8.3M | $5.6M | $51.3M |
| Other LT Assets | $849.0K | $596.0K | $3.3M | $85.0M |
| Total Assets | $638.8M | $628.6M | $1.56B | $1.96B |
| Current Liabilities | $51.9M | $80.7M | $98.0M | $195.4M |
| Accounts Payable | $4.6M | $8.8M | $8.5M | $12.4M |
| Current Leases | $3.1M | $3.6M | $3.8M | $3.9M |
| Deferred Revenue | $5.0M | $28.4M | $21.0M | $21.6M |
| Other Current Liab | $39.1M | $39.9M | $64.7M | $157.5M |
| Long-Term Liabilities | $8.8M | $47.1M | $40.9M | $74.0M |
| LT Operating Leases | $7.6M | $6.2M | $3.0M | $45.3M |
| Other LT Liab | $0 | $0 | $0 | $0 |
| Total Liabilities | $60.7M | $127.8M | $138.9M | $269.4M |
| Shareholders' Equity | $578.1M | $500.8M | $1.42B | $1.69B |
| Paid-In Capital | $939.3M | — | — | — |
| Retained Earnings | $-358.5M | $-570.8M | $-893.1M | $-1.58B |
| AOCI | $-2.7M | $125.0K | $2.9M | $2.6M |
| Total L&E | $638.8M | $628.6M | $1.56B | $1.96B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-174.0M | $-212.2M | $-322.3M | $-684.6M |
| Non-Cash Adjustments | $15.7M | $25.1M | $-14.1M | $-194.6M |
| Working Capital Changes | $22.1M | $68.0M | $35.6M | $228.8M |
| Cash from Operations | $-136.3M | $-119.1M | $-300.9M | $-650.4M |
| Capital Expenditures | $2.8M | $4.2M | $7.1M | $13.3M |
| Cash from Investing | $-190.0M | $-130.1M | $-854.2M | $-38.0M |
| Debt Repayments | $0 | — | — | — |
| Cash from Financing | $346.2M | $93.9M | $1.19B | $851.0M |
| FX Effect | $0 | $0 | $0 | $137.0K |
| Net Change in Cash | $19.9M | $-155.3M | $37.3M | $162.7M |
| Beginning Cash | $320.7M | $340.6M | $185.4M | $222.7M |
| Ending Cash | $340.6M | $185.4M | $222.7M | $385.3M |
Frequently Asked Questions
How does Avidity Biosciences, Inc. make money?
Oncology Therapeutics, Rare Disease Programs, Strategic Licensing and Collaboration Agreements
What are the main risks for RNA?
High burn rate driven by significant R&D and general administrative expenses exceeding $650M, Dependence on success of clinical trials for future revenue streams, Limited operating history and lack of profitability, Potential dilution from equity issuances to fund operations.
What is RNA's competitive advantage?
Proprietary platform technology enabling targeted drug delivery, Strong pipeline of late-stage candidates with potential high-value commercialization partners, Experienced management team with track record in biotech development.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.